NO322572B1 - Pseudopolymorf av (-)-cis-2-(2-klorfenyl)-5,7-dihydroksy-8[4R-(3S-hydroksy-1-metyl)piperidinyl]-4H-1-benzopyran-4-on hydroklorid, fremgangsmate til fremstilling derav, anvendelse derav ved kreftbehandling, samt farmasoytisk sammensetning som innbefatter pseudopolymorfen. - Google Patents

Pseudopolymorf av (-)-cis-2-(2-klorfenyl)-5,7-dihydroksy-8[4R-(3S-hydroksy-1-metyl)piperidinyl]-4H-1-benzopyran-4-on hydroklorid, fremgangsmate til fremstilling derav, anvendelse derav ved kreftbehandling, samt farmasoytisk sammensetning som innbefatter pseudopolymorfen. Download PDF

Info

Publication number
NO322572B1
NO322572B1 NO20023386A NO20023386A NO322572B1 NO 322572 B1 NO322572 B1 NO 322572B1 NO 20023386 A NO20023386 A NO 20023386A NO 20023386 A NO20023386 A NO 20023386A NO 322572 B1 NO322572 B1 NO 322572B1
Authority
NO
Norway
Prior art keywords
methyl
pseudopolymorph
cis
hydrochloride
flavopiridol
Prior art date
Application number
NO20023386A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023386L (no
NO20023386D0 (no
Inventor
Gary L Bafus
Christine M Harrison-Bowman
Gary L Silvey
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20023386D0 publication Critical patent/NO20023386D0/no
Publication of NO20023386L publication Critical patent/NO20023386L/no
Publication of NO322572B1 publication Critical patent/NO322572B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Stereophonic System (AREA)
  • Inorganic Insulating Materials (AREA)
  • Pyrane Compounds (AREA)
NO20023386A 2000-01-18 2002-07-12 Pseudopolymorf av (-)-cis-2-(2-klorfenyl)-5,7-dihydroksy-8[4R-(3S-hydroksy-1-metyl)piperidinyl]-4H-1-benzopyran-4-on hydroklorid, fremgangsmate til fremstilling derav, anvendelse derav ved kreftbehandling, samt farmasoytisk sammensetning som innbefatter pseudopolymorfen. NO322572B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48471700A 2000-01-18 2000-01-18
PCT/US2001/000519 WO2001053293A1 (en) 2000-01-18 2001-01-08 Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one

Publications (3)

Publication Number Publication Date
NO20023386D0 NO20023386D0 (no) 2002-07-12
NO20023386L NO20023386L (no) 2002-09-12
NO322572B1 true NO322572B1 (no) 2006-10-30

Family

ID=23925305

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023386A NO322572B1 (no) 2000-01-18 2002-07-12 Pseudopolymorf av (-)-cis-2-(2-klorfenyl)-5,7-dihydroksy-8[4R-(3S-hydroksy-1-metyl)piperidinyl]-4H-1-benzopyran-4-on hydroklorid, fremgangsmate til fremstilling derav, anvendelse derav ved kreftbehandling, samt farmasoytisk sammensetning som innbefatter pseudopolymorfen.

Country Status (26)

Country Link
EP (1) EP1259507B1 (cs)
JP (1) JP2003520797A (cs)
KR (1) KR100806464B1 (cs)
CN (1) CN1174977C (cs)
AT (1) ATE273303T1 (cs)
AU (1) AU2001226346A1 (cs)
BR (1) BR0107726A (cs)
CA (1) CA2397593C (cs)
CZ (1) CZ301195B6 (cs)
DE (1) DE60104822T2 (cs)
DK (1) DK1259507T3 (cs)
EA (1) EA005247B1 (cs)
ES (1) ES2222332T3 (cs)
HU (1) HUP0204126A3 (cs)
IL (2) IL150638A0 (cs)
MX (1) MXPA02007005A (cs)
NO (1) NO322572B1 (cs)
NZ (1) NZ520280A (cs)
PL (1) PL200696B1 (cs)
PT (1) PT1259507E (cs)
SI (1) SI1259507T1 (cs)
SK (1) SK287404B6 (cs)
TR (1) TR200402036T4 (cs)
TW (1) TWI284129B (cs)
WO (1) WO2001053293A1 (cs)
ZA (1) ZA200205639B (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901472TA (en) 2016-08-23 2019-03-28 Eisai R&D Man Co Ltd Combination therapies for the treatment of hepatocellular carcinoma
AU2018234903B2 (en) 2017-03-16 2024-02-08 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (cs) * 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5908934A (en) * 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs

Also Published As

Publication number Publication date
WO2001053293A1 (en) 2001-07-26
DE60104822D1 (de) 2004-09-16
NZ520280A (en) 2004-04-30
SK287404B6 (sk) 2010-09-07
IL150638A (en) 2009-06-15
ATE273303T1 (de) 2004-08-15
KR100806464B1 (ko) 2008-02-21
CN1174977C (zh) 2004-11-10
PL356165A1 (en) 2004-06-14
PL200696B1 (pl) 2009-01-30
JP2003520797A (ja) 2003-07-08
CZ301195B6 (cs) 2009-12-02
CN1395576A (zh) 2003-02-05
TR200402036T4 (tr) 2004-10-21
MXPA02007005A (es) 2004-09-06
EA200200775A1 (ru) 2002-12-26
PT1259507E (pt) 2004-12-31
ES2222332T3 (es) 2005-02-01
CA2397593C (en) 2009-11-10
CA2397593A1 (en) 2001-07-26
EP1259507B1 (en) 2004-08-11
CZ20022466A3 (cs) 2002-11-13
DK1259507T3 (da) 2004-11-01
HUP0204126A3 (en) 2006-02-28
NO20023386L (no) 2002-09-12
SI1259507T1 (en) 2005-02-28
HUP0204126A2 (hu) 2003-04-28
DE60104822T2 (de) 2005-09-01
ZA200205639B (en) 2003-10-15
NO20023386D0 (no) 2002-07-12
TWI284129B (en) 2007-07-21
SK10362002A3 (sk) 2003-01-09
EA005247B1 (ru) 2004-12-30
BR0107726A (pt) 2002-10-01
EP1259507A1 (en) 2002-11-27
KR20020069361A (ko) 2002-08-30
AU2001226346A1 (en) 2001-07-31
IL150638A0 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
CN107531678B (zh) Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用
CN111601791B (zh) Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用
CN117769560A (zh) Egfr抑制剂的盐、晶型及其组合物和应用
JP2002506868A (ja) 癌治療において用いるためのグラニュラチミド誘導体
US6576647B2 (en) Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one
NO322572B1 (no) Pseudopolymorf av (-)-cis-2-(2-klorfenyl)-5,7-dihydroksy-8[4R-(3S-hydroksy-1-metyl)piperidinyl]-4H-1-benzopyran-4-on hydroklorid, fremgangsmate til fremstilling derav, anvendelse derav ved kreftbehandling, samt farmasoytisk sammensetning som innbefatter pseudopolymorfen.
TWI826013B (zh) 咪唑啉酮衍生物的晶型
NO322626B1 (no) Hydroklorid-etanol-solvatform av (-)-cis-2-(2-klorfenyl)-5,7-dihydroksy-8[4R-(3S-hydroksy-1-metyl)piperidinyl]-4H-1-benzopyran-4-on, fremgangsmate for fremstilling derav og anvendelse derav ved behandling av cancer.
US20160221991A1 (en) Novel triazine derivative
TW202302566A (zh) 喹啉化合物的鹽或晶型及其製備方法和應用
HK1052342A (en) Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
CN113717111A (zh) 喹唑啉类化合物的晶型及其制备方法
CN114644616A (zh) 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法

Legal Events

Date Code Title Description
MK1K Patent expired